DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy -- a highly inaccurate method that most ...
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will ...
If the dermatologist determines that a DermTech Melanoma Test is warranted, they will order the Melanoma Test for the patient. The DermTech Adhesive Skin Collection Kit, which contains the DermTech ...
John Dobak had learned about genomic testing in the 1990s and been tracking the evolution of this new approach to detecting cancer, and other diseases. Yet few had been able to turn it into an easy to ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion ...
DermTech, a San Diego biotechnology company that developed a noninvasive melanoma test, is reducing its workforce by 15 percent to shave off operating expenses. The company announced last week that it ...
Add Yahoo as a preferred source to see more of our stories on Google. ((SL Advertiser)) For additional information on the DermTech Melanoma Test, go to DermTech.com ...
Summer Moon, DO, FAAD, Board-certified Dermatologist at Bay Dermatology joins Gayle Guyardo the host of the nationally syndicated health and wellness show Bloom to discuss the importance of sun safety ...
DermTech's new product could revolutionize how doctors test for skin cancer. 10x Genomics is turbocharging research in cells and genes. Both companies offer disruptive new solutions in their niches of ...
San Diego’s DermTech has cut about 40 jobs and shelved certain research programs to focus on its main product — a non-invasive, genomics-based diagnostic test for melanoma. The company, which went ...
It's probably going to take a while for DermTech to gain widespread acceptance among doctors for its genomics-based melanoma test. Keith Speights: Very quickly, Brian, let's hit one question before we ...
Shares of precision dermatology company DermTech Inc DMTK are rallying Thursday after receiving Medicare coverage for its diagnostic test to rule out skin cancer. The California-based company said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results